{"doi":"10.1002/jhm.2449","title":"Fecal microbiota transplantation for the treatment of <i>Clostridium difficile</i> infection","abstract":"<jats:p><jats:italic>Clostridium difficile</jats:italic>, a major cause of healthcare‐associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of <jats:italic>C difficile</jats:italic> infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long‐term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed. <jats:italic>Journal of Hospital Medicine</jats:italic> 2016;11:56–61. © 2015 Society of Hospital Medicine</jats:p>","journal":"Journal of Hospital Medicine","year":2016,"id":607557,"datarank":0.6414999178524083,"base_score":4.276666119016055,"endowment":4.276666119016055,"self_citation_contribution":0.6414999178524083,"citation_network_contribution":0.0,"self_endowment_contribution":0.6414999178524083,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":71,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":226785,"name":"Nasia Safdar","orcid":"0000-0003-3946-0437","position":1,"is_corresponding":false},{"id":374929,"name":"Krishna Rao","orcid":"0000-0002-9213-7850","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Fecal microbiota transplantation for the treatment of <i>Clostridium difficile</i> infection","abstract":"<jats:p><jats:italic>Clostridium difficile</jats:italic>, a major cause of healthcare‐associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of <jats:italic>C difficile</jats:italic> infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long‐term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed. <jats:italic>Journal of Hospital Medicine</jats:italic> 2016;11:56–61. © 2015 Society of Hospital Medicine</jats:p>","is_dataset_classified":null,"base_score":4.276666119016055,"endowment":4.276666119016055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26344412","pmcid":"PMC4908581","openalex_id":"https://openalex.org/W1900902556","authors":[],"funders":[{"funder_name":"Americans Independence Center","grant_id":"AG-024824","title":null},{"funder_name":"Michigan Institute for Clinical and Health Research","grant_id":"2UL1TR000433","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P30 AG024824","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"R21 AI120599","title":null},{"funder_name":"NIA NIH HHS","grant_id":"R03 AG040669","title":null},{"funder_name":"NCATS NIH HHS","grant_id":"UL1 TR000433","title":null},{"funder_name":"CSRD VA","grant_id":"I01 CX000391","title":null}],"total_grants":7,"fwci":7.3538,"citation_percentile":0.97961927,"influential_citations":0,"citation_trend":[{"year":2015,"count":2},{"year":2016,"count":10},{"year":2017,"count":17},{"year":2018,"count":10},{"year":2019,"count":9},{"year":2020,"count":5},{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":4},{"year":2024,"count":7},{"year":2025,"count":2},{"year":2026,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjhm.2449","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/jhm.2449","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jhm.2449","host_type":"publisher"},{"url":"https://shmpublications.onlinelibrary.wiley.com/doi/pdf/10.1002/jhm.2449","host_type":"publisher"},{"url":"https://doi.org/10.1002/jhm.2449","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26344412","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4908581","host_type":"repository"}],"fields_of_study":["Clostridium difficile and Clostridium perfringens research","Gastrointestinal motility and disorders","Microscopic Colitis"],"mesh_terms":["Gastrointestinal Microbiome","Fecal Microbiota Transplantation","Anti-Bacterial Agents","Clostridium Infections","Diarrhea","Enterocolitis, Pseudomembranous","Feces","Humans","Recurrence","Clostridioides difficile"],"keywords":["Fecal bacteriotherapy","Clostridium difficile","Medicine","Clostridium Infections","C difficile","Feces","Microbiology","Transplantation","Immunology","Intensive care medicine","Internal medicine","Antibiotics","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T06:35:18.707877Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}